Works by SAWHNEY, SANGEETA

Results: 16

Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 854, doi. 10.1111/dom.14271

By:

Danne, Thomas;
Edelman, Steven;
Frias, Juan Pablo;
Ampudia‐Blasco, Francisco Javier;
Banks, Philip;
Jiang, Wenjun;
Davies, Michael J.;
Sawhney, Sangeeta

Publication type:

Article

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2440, doi. 10.1111/dom.13825

By:

Baker, Claire;
Wason, Suman;
Banks, Phillip;
Sawhney, Sangeeta;
Chang, Anna;
Danne, Thomas;
Gesty‐Palmer, Diane;
Kushner, Jake A.;
McGuire, Darren K.;
Mikell, Frank;
O'Neill, Mark;
Peters, Anne L.;
Strumph, Paul

Publication type:

Article

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.

Published in:

2020

By:

Peters, Anne L.;
McGuire, Darren K.;
Danne, Thomas;
Kushner, Jake A.;
Rodbard, Helena W.;
Dhatariya, Ketan;
Sawhney, Sangeeta;
Banks, Phillip;
Jiang, Wenjun;
Davies, Michael J.;
Lapuerta, Pablo

Publication type:

journal article

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Published in:

2019

By:

Danne, Thomas;
Cariou, Bertrand;
Buse, John B.;
Garg, Satish K.;
Rosenstock, Julio;
Banks, Phillip;
Kushner, Jake A.;
McGuire, Darren K.;
Peters, Anne L.;
Sawhney, Sangeeta;
Strumph, Paul

Publication type:

journal article

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

Published in:

2018

By:

Buse, John B.;
Garg, Satish K.;
Rosenstock, Julio;
Bailey, Timothy S.;
Banks, Phillip;
Bode, Bruce W.;
Danne, Thomas;
Kushner, Jake A.;
Lane, Wendy S.;
Lapuerta, Pablo;
McGuire, Darren K.;
Peters, Anne L.;
Reed, John;
Sawhney, Sangeeta;
Strumph, Paul

Publication type:

journal article

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.

Published in:

2018

By:

Danne, Thomas;
Cariou, Bertrand;
Banks, Phillip;
Brandle, Michael;
Brath, Helmut;
Franek, Edward;
Kushner, Jake A.;
Lapuerta, Pablo;
McGuire, Darren K.;
Peters, Anne L.;
Sawhney, Sangeeta;
Strumph, Paul

Publication type:

journal article

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.

Published in:

Liver International, 2024, v. 44, n. 4, p. 966, doi. 10.1111/liv.15816

By:

Alkhouri, Naim;
LaCerte, Carl;
Edwards, Jeffrey;
Poordad, Fred;
Lawitz, Eric;
Lee, Lois;
Karan, Sharon;
Sawhney, Sangeeta;
Erickson, Mary;
MacConell, Leigh;
Zaru, Luna;
Chen, Jianfen;
Campagna, Jason

Publication type:

Article

Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.

Published in:

Diabetes & Vascular Disease Research, 2021, v. 18, n. 1, p. 1, doi. 10.1177/1479164121995928

By:

Rodbard, Helena W;
Giaccari, Andrea;
Cariou, Bertrand;
Garg, Satish;
Davies, Michael J;
Seth, Kiernan;
Sawhney, Sangeeta

Publication type:

Article

136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-136-LB

By:

CHERNEY, DAVID;
FERRANNINI, ELE;
UMPIERREZ, GUILLERMO E.;
PETERS, ANNE L.;
ROSENSTOCK, JULIO;
CARROLL, AMY K.;
SAWHNEY, SANGEETA;
BANKS, PHILLIP L.;
JIANG, WENJUN;
LAPUERTA, PABLO

Publication type:

Article

135-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-135-LB

By:

CHERNEY, DAVID;
FERRANNINI, ELE;
UMPIERREZ, GUILLERMO E.;
PETERS, ANNE L.;
ROSENSTOCK, JULIO;
CARROLL, AMY K.;
LAPUERTA, PABLO;
BANKS, PHILLIP L.;
JIANG, WENJUN;
SAWHNEY, SANGEETA

Publication type:

Article

1129-P: Effect of Sotagliflozin Added to Insulin Therapy on Beta-Hydroxybutyrate in Patients with Type 1 Diabetes.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1129-P

By:

PETERS, ANNE L.;
DANNE, THOMAS;
SAWHNEY, SANGEETA;
BANKS, PHILLIP L.;
DAVIES, MICHAEL J.;
LAPUERTA, PABLO

Publication type:

Article

1103-P: Balancing the Risk of DKA and Severe Hypoglycemia with Sotagliflozin in Adults with Type 1 Diabetes.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1103-P

By:

PETTUS, JEREMY;
CARIOU, BERTRAND;
SAWHNEY, SANGEETA;
BANKS, PHILLIP L.;
DAVIES, MICHAEL J.;
LAPUERTA, PABLO

Publication type:

Article

1102-P: Impact of Treatment with Sotagliflozin on the Incidence of Severe Hypoglycemia in Patients with T1D.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1102-P

By:

PETTUS, JEREMY;
DANNE, THOMAS;
PETERS, ANNE L.;
CARROLL, AMY K.;
SAWHNEY, SANGEETA;
JIANG, WENJUN;
BANKS, PHILLIP L.;
MCGILL, JANET B.

Publication type:

Article

1100-P: Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults with Type 1 Diabetes.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1100-P

By:

HANDELSMAN, YEHUDA;
GIACCARI, ANDREA;
SAWHNEY, SANGEETA;
BANKS, PHILLIP L.;
DAVIES, MICHAEL J.;
LAPUERTA, PABLO

Publication type:

Article

1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1220-P

By:

DANNE, THOMAS;
PETTUS, JEREMY;
GIACCARI, ANDREA;
CARIOU, BERTRAND;
RODBARD, HELENA W.;
WEINZIMER, STUART A.;
BONNEMAIRE, MIREILLE;
SAWHNEY, SANGEETA;
WANG, STELLA;
CASTRO, RITA;
GARG, SATISH K.

Publication type:

Article

1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1212-P

By:

RODBARD, HELENA W.;
GIACCARI, ANDREA;
DAVIES, MICHAEL J.;
SAWHNEY, SANGEETA;
WANG, STELLA;
GARG, SATISH K.;
CARIOU, BERTRAND

Publication type:

Article

Works by SAWHNEY, SANGEETA

Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m<sup>2</sup>.

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

HbA<sub>1c</sub> and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.

Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.

136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment.

135-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment.

1129-P: Effect of Sotagliflozin Added to Insulin Therapy on Beta-Hydroxybutyrate in Patients with Type 1 Diabetes.

1103-P: Balancing the Risk of DKA and Severe Hypoglycemia with Sotagliflozin in Adults with Type 1 Diabetes.

1102-P: Impact of Treatment with Sotagliflozin on the Incidence of Severe Hypoglycemia in Patients with T1D.

1100-P: Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults with Type 1 Diabetes.

1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA<sub>1c</sub> Level at 52 Weeks in Adults with T1D.

1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials.